VANCOUVER, British Columbia, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise that its HeartSentry 1st generation product has successfully passed all requisite bench tests in preparation for upcoming clinical trials and the units have been formally released and delivered to Diablo Clinical Research.
The HeartSentry product presents a new approach to non-invasive cardiovascular health diagnostics through the measurement and monitoring of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. This 1st generation product is the result of over 15 years of research at Lawrence Berkeley National Labs, and under the auspices of Lexington Biosciences is at a late-stage of preparedness for human clinical trials to commence shortly in the San Francisco Bay Area.
The initial production run units are all slated for the upcoming trials, and with the conclusion of bench testing this week they have been shipped to the investigative clinic. Months of bench tests validated software integrity in combination with a series of mechanical and electrical inspections aimed at ensuring safe operation within a statistically quantifiable operating environment designed to deliver measurably consistent results.
Lexington’s President Eric Willis comments, “The team has worked diligently over the past several months to ensure the product is ready for human trials. As of today, we have signed off on all operational aspects of the device, including the documentation for operation and data interpretation. The product has been transferred to the investigative team and we have completed the device and study training with the researchers. We look forward to enrolling the first patients very soon and are excited to have our product in the hands of clinical professionals who we are certain will do a very thorough job of examining HeartSentry’s efficacy. I am pleased to report we are now one step closer to providing what is currently being discussed as a potentially disruptive tool in the early diagnosis of heart disease for healthcare professionals as well as patients around the world.”
To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on Facebook, Twitter and LinkedIn.
About Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.
On Behalf of the Board,
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Lexington Biosciences, Inc.
+1 (800) 320-2640
Renmark Financial Communications Inc.
Laura Welsh: firstname.lastname@example.org
Tel: (416) 644-2020 or (514) 939-3989
© 2018 Canjex Publishing Ltd. All rights reserved.